Given after surgery, AZ’s Tagrisso prevents lung cancer coming backAstraZeneca opened its account at this year’ virtual ASCO meeting with data showing that adjuvant (post-surgery) use of Share XGiven after surgery, AZ’s Tagrisso prevents lung cancer coming backhttps://pharmaphorum.com/news/given-after-surgery-azs-tagrisso-prevents-lung-cancer-coming-back/
BMS eyes August FDA verdict for Opdivo/Yervoy in first-line lung cancerBristol-Myers Squibb is trying again to get approval for its checkpoint inhibitor combination of Opdivo and Yervoy in Share XBMS eyes August FDA verdict for Opdivo/Yervoy in first-line lung cancerhttps://pharmaphorum.com/news/bms-eyes-august-fda-verdict-for-opdivo-yervoy-in-first-line-lung-cancer/
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdictEli Lilly’s cancer drug Cyramza has inched closer to a new indication in first-line non-small cell lung cancer Share XLilly’s Cyramza closer to first-line lung cancer use after ODAC verdicthttps://pharmaphorum.com/news/lilly-closes-on-first-line-lung-cancer-use-after-odac-verdict/
Trial answers the KRAS question for Keytruda in lung cancerMerck & Co’s Keytruda reigns supreme among immunotherapies for non-small cell lung cancer (NSCLC), and new data looks Share XTrial answers the KRAS question for Keytruda in lung cancerhttps://pharmaphorum.com/news/trial-answers-the-kras-question-for-keytruda-in-lung-cancer/
Roche steps up Merck challenge with first-line NSCLC approval in USRoche has scored another FDA approval for Tecentriq alongside chemotherapy for previously-untreated, non-squamous non-small cell lung cancer (NSCLC), Share XRoche steps up Merck challenge with first-line NSCLC approval in UShttps://pharmaphorum.com/news/roche-continues-merck-challenge-with-first-line-nsclc-approval-in-us/
Takeda sets sights on first-line lung cancer market with new Alunbrig dataPfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a Share XTakeda sets sights on first-line lung cancer market with new Alunbrig datahttps://pharmaphorum.com/news/takeda-sets-sights-on-first-line-lung-cancer-market-with-new-alunbrig-data/
Finally, AZ claims a win with Imfinzi/tremelimumab cancer comboAstraZeneca’s development of checkpoint inhibitor combination Imfinzi and tremelimumab has chalked up serial trial failures in the last Share XFinally, AZ claims a win with Imfinzi/tremelimumab cancer combohttps://pharmaphorum.com/news/finally-az-claims-a-win-with-imfinzi-tremelimumab-cancer-combo/
BMS gets a much-needed win with Opdivo in first-line lung cancerBristol-Myers Squibb’s attempts to challenge Merck & Co’s dominance in previously-untreated non-small cell lung cancer (NSCLC) have disappointed Share XBMS gets a much-needed win with Opdivo in first-line lung cancerhttps://pharmaphorum.com/news/bms-gets-a-much-needed-win-with-opdivo-in-first-line-lung-cancer/
Relief for Lilly as drug from $8bn Loxo deal clears pivotal trialEli Lilly’s $8 billion acquisition of Loxo Oncology looks like it could pay off, with new data for Share XRelief for Lilly as drug from $8bn Loxo deal clears pivotal trialhttps://pharmaphorum.com/news/relief-for-lilly-as-drug-from-8bn-loxo-deal-clears-pivotal-trial/
